Table 1.
Demographics of participating patients
| Patients (n=6228) | |
|---|---|
| Sex | |
| Male | 811 (13·0%) |
| Female | 5417 (87·0%) |
| Age category | |
| <18 years | 69 (1·1%) |
| 18–29 years | 772 (12·4%) |
| 30–39 years | 1312 (21·1%) |
| 40–49 years | 1337 (21·5%) |
| 50–59 years | 1578 (25·3%) |
| 60–69 years | 843 (13·5%) |
| ≥70 years | 232 (3·7%) |
| Missing | 85 (1·4%) |
| Rheumatic disease | |
| Rheumatoid arthritis | 2766 (44·4%) |
| Systemic lupus erythematosus | 1964 (31·5%) |
| Sjögren's syndrome | 652 (10·5%) |
| IgG4-related disease | 64 (1·0%) |
| Undifferentiated connective tissue disease | 208 (3·3%) |
| Other | 574 (9·2%) |
| DMARDs* | |
| Corticosteroids | 1193 (51·7%) |
| Hydroxychloroquine | 616 (26·7%) |
| Leflunomide | 967 (41·9%) |
| Thalidomide | 54 (2·3%) |
| Methotrexate | 565 (24·5%) |
| Mycophenolate mofetil | 224 (9·7%) |
| Biological DMARDs | 56 (2·4%) |
| Targeted synthetic DMARDs | 36 (1·6%) |
| Tacrolimus | 90 (3·9%) |
| Cyclophosphamide | 17 (0·7%) |
| Cyclosporine A | 93 (4·0%) |
| Missing | 3919 |
Data are n or n (%). DMARDs=disease-modifying anti-rheumatic drugs.
*
Data on DMARD use are provided for 2309 patients, and percentages reported for this subpopulation. Some patients were taking two or more DMARDs.